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The objective of this review is to present examples of lead compounds identified from biological
material (fungi, plant extracts and agro-industry material) and of possible interest in the field
of a pharmacological approach to the therapy of b-thalassemia using molecules able to
stimulate production of fetal hemoglobin (HbF) in adults. Concerning the employment of HbF
inducers as potential drugs for pharmacological treatment of b-thalassemia, the following
conclusions can be reached: (i) this therapeutic approach is reasonable, on the basis of the
clinical parameters exhibited by hereditary persistence of fetal hemoglobin patients, (ii) clinical
trials (even if still limited) employing HbF inducers were effective in ameliorating the symptoms
of b-thalassemia patients, (iii) good correlation of in vivo and in vitro results of HbF synthesis
and g-globin mRNA accumulation indicates that in vitro testing might be predictive of in vivo
responses and (iv) combined use of different inducers might be useful to maximize HbF, both in
vitro and in vivo. In this review, we present three examples of HbF inducers from the natural
world: (i) angelicin and linear psoralens, contained in plant extracts from Angelica arcangelica
and Aegle marmelos, (ii) resveratrol, a polyphenol found in grapes and several plant extracts
and (iii) rapamycin, isolated from Streptomyces hygroscopicus.
Keywords: fetal hemoglobin–b-thalassemia–rapamycin–medicinal plants–resveratrol–red
wine–psoralens
b-Thalassemias, Sickle Cell Anemia (SCA)
and Hereditary Persistance of Fetal
Hemoglobin (HPFH)
The b-thalassemias are characterized by a very heterogen-
eous group of inherited mutations causing abnormal
expression of globin genes, leading to total absence or
quantitative reduction of synthesis of b-globin chains (1–3).
This disease is frequent in the Mediterranean area,
Middle East, Africa and Asia. The reduction of
b-globin chains is associated with a corresponding
excess of the complementary a-globin chain in erythroid
cells that causes premature hemolysis of red blood cells
and destruction of erythroid precursors in the bone
marrow and extramedullary sites (ineffective erythropoi-
esis) (4–7). More than 200 different mutations have been
identified in b-thalassemia patients (1–3,8,9), including
deletions of the b or b gene region, stop codons leading
to premature termination of a non-functional b-globin
chain, mutations suppressing correct maturation of the
b-globin RNA precursor.
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properly cited.SCA is a common recessively inherited disorder of
hemoglobin caused by a point mutation affecting the
coding sequence of the b-globin gene, causing a substitu-
tion of glutamic acid by valine at the sixth position of
b-globins of hemoglobin S (HbS) (10). This amino acid
substitution leads to a drastic reduction in the solubility of
the deoxy form of HbS. Under hypoxic conditions, deoxy-
HbS molecules polymerize inside the cells, forming rigid,
sickled cells. SCA is highly frequent in sub-Saharan Africa,
the Middle East and Mediterranean areas, the Indian sub-
continent, the Caribbean and South America. The homo-
zygous state of SCA is associated with complications and
a reduced life expectancy (10,11).
Several observations lead to the conclusion that produc-
tion of fetal hemoglobin (HbF) can functionally compen-
sate for the absence of b-globin chain production (12–15),
including the very interesting finding that a group of
genetic mutations, known as hereditary persistence of fetal
hemoglobin (HPFH), are associated with high levels of
HbF in adults (16–19) resulting in a mild phenotype. Most
of the HPFH patients homozygous for b-thalassemia do
not need blood transfusion. Therefore, there has been
considerable interest in recent years in finding ways of
increasing production of HbF and reactivate the g-globin
genes (20–29).
In Table 1, a list of HbF inducers is reported.
Unfortunately, several of these drugs have low efficacy
and specificity, and some of them are potentially carcino-
genic. Therefore, there is an urgent need to (i) develop
experimental model systems for a large screening of HbF
inducers and (ii) identify new types of agents that can
induce HbF production with greater efficiency and lower
toxicity (20).
Clinical Trials
Clinical trials aimed at increasing HbF synthesis in
b-thalassemia and SCA patients have included administra-
tion of cell-cycle-specific agents, hematopoietic growth
factors and short-chain fatty acids, all of which stimulate
g-globin synthesis by different mechanisms. Compounds
such as 5-azacytidine, hydroxyurea (HU) and butyrate
analogues have been used most frequently (30–39)
(Table 2). As a representative example, Yavarian et al.
(30) reported the treatment with HU in 133 patients
diagnosed with transfusion-dependent b-thalassemia.
These patients were classified into three categories of
response: a good response (61%) in patients who shifted
from monthly blood transfusion dependency to a stable
transfusion-free condition; a moderate response (23%) in
patients who remained transfusion dependent but at longer
intervals (6 months or more), and non-response in patients
who, after 1 year of treatment, remained at the same level
of transfusion dependency. As far as demethylating agents
tested in Phase I/II studies, decitabine, used at DNA
hypomethylating, but non-cytotoxic doses, was well
tolerated and effective in increasing HbF and total Hb
levels in patients affected by hemoglobin disorders (40,41).
Therapy with butyrates has been also reported (42). When
all these clinical data are considered together, it appears
that HbF inducers are clinically beneficial for patients
affected by b-thalassemia and SCA.
Experimental Model Systems to Identify Novel
Inducers of Fetal Hemoglobin
Reporter Genes under the Transcriptional Control of the
g-Globin Promoter
Several groups described the use of reporter genes
[such as luciferase and green fluorescence protein
(GFP)] under the transcriptional control of the
Table 1. Inducers of differentiation and HbF in human erythroid cells*
Inducers Mechanism of action
HU Inhibition of DNA synthesis
5-Azacytidine and citarabine Hypomethylation of DNA
Butyrates, tricostatin,
apicidin and scriptaid
Inhibition of HDAC activity
Mithramycin, cisplatin and analogues,
tallimustine and analogues, angelicin
DNA-binding activity
Rapamycin and everolimus FRAP-mTOR signal
transduction targeting
Triple-helix oligonucleotides Activation of g-globin
gene transcription
Peptide nucleic acids (PNAs) Sequence-selective
promoter activation
*Modified from Gambari and Fibach (55).
Table 2. Clinical trials employing HU as in vivo inducer of fetal
hemoglobin
Number of
patients
treated
a
Genotype/
phenotype
b
Number
of patients
responding
to the
treatment
c
References
2 b-Thalassemia
intermedia
2 (100%) Bradai et al., (31)
5 b-Thalassemia
major
5 (100%) Bradai et al. (31)
36 b-Thalassemia
major
25 (69%) Alebouyeh et al. (32)
133 b-Thalassemia
major
81 (61%) Yavarian et al. (30)
37 b-Thalassemia
intermedia
26 (70%) Dixit et al. (33)
166 b-Thalassemia
intermedia
83 (50%) Karimi et al. (34)
42 HbE/b -Thalassemia 50% Singer et al. (35)
aDosages were 5–20mgkg
 1day
 1;
bOnly patients needing transfusions
are included;
cTransfusion-free patients.
142 Fetal hemoglobin inducers from natural worldGg-globin gene promoter. For instance, Skarpidi et al.
(43) developed a rapid and efficient method for detecting
HbF inducers, based on a recombinant DNA construct
in which the coding sequences of two different luciferase
reporter genes, firefly and renilla, are substituted for those
of human
Gg-globin and b-globin genes, respectively.
Cellular genomic reporter assays for screening and evalua-
tion of HbF inducers were also developed by introducing
reporter genes within an intact b-globin gene locus.
This approach has described and validated by Vadolas
et al. (44), who developed a stable cellular genomic
reporter assays based on the GFP gene under the
Gg-globin promoter in the intact human b-globin locus.
The results obtained firmly demonstrate that both these
approaches are suitable for the high-throughput screening
of molecules able to increase g-globin promoter directed
transcription (45).
Human Erythroid-like K562 Cells
The human erythroid-like K562 cell line, isolated
and characterized by Lozzio and Lozzio (46) from a patient
with chronic myelogenous leukemia in blast crisis, has been
extensively employed as a very useful in vitro model to study
the molecular mechanism(s) regulating the expression
of embryonic and fetal human globin genes (47), as well
as to determine the therapeutic potential of new differentia-
tion-inducing compounds (47–51). K562 cells grow in
culture as single, undifferentiated, cells in suspension,
with low production of hemoglobins (see Fig. 1A, left).
Figure 1. The K562 and human erythroid precursors cell systems for screening of inducers of HbF. (A) Pellets of uninduced (left) and erythroid
induced (right) K562 cells. Only pellets from induced cells are red, indicating hemoglobin production. (B,C) Northern blotting analysis of
uninduced and erythroid induced cells. Hybridization was carried on with a g-globin (B) or a b-actin (C) probes. The increase of signal in
erythroid induced cells (B, lines 2 and 4 from the left) indicates an increase of production of g-globin mRNA. Minor changes are observed
studying actin mRNA (C). (D,E) Quantitative RT-PCR analysis documenting the increase of g-globin mRNA in K562 cells following induction
(black squares) (D); minor changes were found in analysis of actin mRNA content (E). (F) Erythroid cells in culture. Benzidine staining of cells
from day 8 Phase II cultures. Cells were smeared on a glass slide using a cytocentrifuge, and stained with benzidine. Mature erythroid
Hb-containing cells, which are benzidine positive (B
+) are arrowed. (G) A red pellet of erythroid precursor cells. (H) Fold increase of g-globin
mRNA content in erythroid precursor cells treated with mithramycin in comparison to control untreated cells (white box). (I) HPLC
chromatogram of hemoglobins produced by cultured erythroid cells. Control (upper chromatogram) and erythroid-induced (lower chromatogram)
cells were harvested from day 12 cultures, washed and lysed. The hemoglobins in the lysate were separated on cation-exchange HPLC.
The peaks are labeled with the corresponding hemoglobin type. Increase in the proportion of HbF is detectable in lysates from erythroid
induced cells. Modified from Gambari and Fibach (55).
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few days with a significant increase in the production of
hemoglobins and g-globin mRNA (Fig. 1A–E) (51).
Erythroid Progenitors from Peripheral Blood
Large cultures of relatively pure and synchronized
erythroid cell population can be obtained from peripheral
blood and compounds can be added on different days
when the culture consists of cells at specific stages of
maturation. In the procedure developed by Fibach et al.
(52), the culture is divided into two phases: an EPO-
independent phase, in which peripheral blood cells are
first cultured in the presence of a combination of growth
factors, but in the absence of EPO. In the second phase,
the culture, supplemented with EPO, generates orthochro-
matic normoblasts that differentiate, decrease in size and
accumulate Hb, generating aggregates assuming a reddish
color (Fig. 1F, arrowed cells). This system recapitulates
many aspects of in vivo erythropoiesis including globin
RNA metabolism, cell cycle kinetics, expression of cell
surface antigens, iron and ferritin metabolism and
transcription factors (53–55). Therefore, several research
groups have used this system to study the effects of
hundreds of compounds, including butyroids (52), hemin
(53) and EPO (54). The globin gene expression can be
monitored analyzing the fold increase of globin mRNA in
respect to control untreated cells (Fig. 1H). Hb content of
the developing erythroid cells (Fig. 1G) can be measured
by a variety of techniques, the most used of which is
cation-exchange HPLC for hemoglobins (Fig. 1I).
Correlation Between In Vitro Effects of HbF
Inducers and In Vivo Treatment
As far as predictivity of in vitro analyses is concerned,
several data suggests a correlation between the in vitro
results on erythroid precursor cells isolated from
b-thalassemia and SCA patients and the response of the
treated patients to therapy. The correlation of in vivo and
in vitro results of HbF synthesis and g-globin mRNA
suggest that in vitro testing may predict the in vivo
response (55). This will prevent both expensive and
potentially risky treatment from patients who do not
respond to treatment and suggest an alternative treatment
(e.g. by other agents).
Inducers of HbF Production
The studies published on potential HbF inducers indicate
that they can be grouped in several classes, with different
mechanisms of action (Table 1) (55). Several inducers
inhibit histone deacethylase (HDAC) activity (26). While
most inducers display inhibitory effects on cell growth, a
limited number of them stimulate increase of HbF
without effecting cell proliferation (55). Erythroid pre-
cursor cells from b-thalassemia patients differ in their
response to the same inducer. Furthermore, a combined
use of HbF inducers displaying a different mechanism of
action might improve the results. Finally, the use
of oligonucleotide (ODN)-based approach might help in
designing specific treatments for different types of
b-thalassemia (55).
HbF Inducers from the Natural World
Several reviews and papers have been published on the
possible use of extracts from medicinal plants for
biomedical purposes (56–65) including therapeutic strate-
gies for the treatment of a number of diseases such as
dyslipidemia (66) and aterosclerosis (67), hepatitis (68),
inflammatory diseases (69,70), osteoporosis (62), bacterial
and virus infections (71–73).
In the case of hemoglobinopathies, only few examples are
available. For instance, Niprisan (Nix-0699), a ethanol/
water extract developed in Nigeria from indigenous plants,
has a strong antisickling effect, demonstrated by a
significant prolongation of the delay time prior to deoxy-
HbS polymerization when compared with that of untreated
HbS samples. The solubility of deoxy-HbS significantly
increased upon treatment with Nix-0699. Niprisan was
found to improve the survival rates of transgenic sickle-cell
mice under acute severe hypoxic conditions. Finally, a
Phase II study suggests that this phytomedicine is effective
in reducing episodes of SCA crisis associated with severe
pain over a 6-month period, in 82 participants (74,75).
On the contrary, in respect to the employment of
products from the natural world for HbF production,
few data are available (Table 3). We present in this
review some recently reported examples.
Linear and Angular Furocoumarins: Potent Inducers of
Erythroid Differentiation and HbF Production
A possible employment of plant extracts on the
identification of novel HbF inducers has been obtained
studying the antiproliferative activity of several extracts
from medicinal plants on different tumor cell lines,
Table 3. Inducers of HbF from natural sources
Inducer Source Biological effects References
Bergaptene A. marmelos Erythroid
differentiation
of K562 cells
Lampronti et al. (65)
Angelicin A. arcangelica HbF production Lampronti et al. (78)
Rapamycin S. hygroscopicus HbF production Mischiati et al. (114)
Fibach et al. (116)
Resveratrol Red wine, grape
skin and
darakchasava
HbF production Rodrigue et al. (101)
Mithramycin Streptomyces
species
HbF production Bianchi et al. (51)
Fibach et al. (77)
144 Fetal hemoglobin inducers from natural worldincluding the K562 cell line (64). Interestingly, antiproli-
ferative activity of extracts from Aegle marmelos on K562
cells was found to be associated with activation of
erythroid induction (65). As published in several papers,
HbF inducers are usually potent inducers of K562 cells
(55,76,77). Accordingly, GC/MS analysis of A. marmelos
allowed us to identify several molecules, including
5-methoxypsoralen (5-MOP, Fig. 2), which we demons-
trated to be responsible for erythroid induction of K562
cells (78). 5-MOP belongs to a well-known class of
molecules (psoralen derivatives) that have been extensively
studied in the past (79–90) and demonstrated to retain
interesting biological effects on eukaryotic cells, allowing
biomedical applications and the development of clinical
trials (90–100). The biological importance of furocoumar-
ins mainly focuses on their more relevant applications in
photochemotherapy as pointed out in several reviews
(97–99). In particular, psoralens have been proposed and
used in psoralens-UVA treatment (PUVA) for psoriasis,
vitiligo and mycosis fungoides (T-cell lymphoma) (98). It is
generally accepted that these molecules cause cell damage
by covalent binding to DNA following UVA irradiation; in
fact, they exhibit a planar tricyclic structure with two
photoreactive sites (3,4-pyrone and 40,50-furan double
bonds). The initial intercalation and interaction with
double-stranded DNA are not characterized by covalent
bonds, but, upon absorption of a photon of UVA, a
pyrimidine residue (preferentially a thymine) of the DNA,
covalently binds to the first photoreactive site with a
5,6-double bond. The resulting monoadduct can form
a diadduct by absorbing a second photon, if a new
pyrimidine on the opposite strand of DNA is available
for an interstrand cross-link. On the contrary, angular
psoralens (such as angelicin), are monofunctional isopsor-
alen isomers and cannot create interstrand cross-links
because of their angular geometric structure (81–83).
Figure 2. Identification of linear and angular furocoumarins as inducers of HbF. Scheme depicting the experimental approach to identify bergapten
(5-MOP) in extracts from A. marmelos (78). The structures of bergapten and the angular analogue angelicin are shown in the right part of the panel.
The fold increase of g-globin mRNA and the percentage of HbF in erythroid precursor cells from human healthy donors are shown in the lower-left
part of the panel. The content of g-globin mRNA has been quantified by RT-PCR, the percentage of HbF by HPLC. These data are modified from
Lampronti et al. (78).
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monofunctional photobinding, thus reducing undesirable
side effects, especially long-term ones such as genotoxicity
and risk of skin cancer.
For these reasons, we focused our attention on
angelicin (78). We demonstrated that angelicin is a
powerful inducer of (i) erythroid differentiation of K562
cells, (ii) increase of HbF in erythroid progenitors from
normal subjects and (iii) increase of g-globin mRNA in
erythroid precursor cells isolated from b-thalassemia
patients. In the lower part of Fig. 2 is depicted a
representative experiment demonstrating increase of
g-globin mRNA and HbF production in erythroid
precursor cells treated with angelicin. Interestingly,
the efficiency of the induction obtained is higher than
that displayed by HU, the most used HbF inducer
in clinical trials of patients affected by b-thalassemia
and SCA (78).
Resveratrol: A HbF Inducer Mimicking the Biological
Activity of Hydroxyurea
Resveratrol (3,5,40-trihydroxystilbene, ‘E’ form) (101–111)
(Fig. 3 for chemical structure) is a natural phytoalexin
present in large quantity in red wine, preferentially in
the skin of grapes (104). The content of resveratrol is
50–100mgmg
 1 of fresh skin and 1.3–3mgl
 1 of red wine
(104,108). In addition, resveratrol is a constituent of
‘Darakchasava’ (1.3–6mgl
 1), an ayurvedic medicine
from India (102).
This polyphenol has been demonstrated to inhibit
ribonucleotide reductase with an efficiency higher than
HU (105). Rodrigue et al. (101) found that resveratrol
possesses similar properties to HU toward erythroid
differentiation. They firmly demonstrated that resveratrol
induces differentiation of K562 cells and augmentation of
HbF in erythroid precursor cells isolated from eight sickle
cell patients. Comparative analyses demonstrated that
resveratrol, as HU, inhibits intracellular adhesion mole-
cule-1 (ICAM-1) and VCAM-1 expression by endothelial
cells. In addition, resveratrol possesses other properties
similar to HU, including induction of nitric oxide synthase
in cultured pulmonary endothelial cells and inhibition of
human platelet aggregation in vitro. Interestingly, resvera-
trol exhibited minimal toxicity on normal hematopoietic
cells, as suggested by Cle ´ ment et al. (111).
In our laboratory, when erythroid precursor cells from
normal subjects were treated with increasing concentra-
tions of resveratrol and analysis of accumulation of
globin mRNA sequences was performed by quantitative
RT-PCR, a clear increase in accumulation of g-globin
mRNA content was found (lower part of Fig. 3). Increase
in accumulation of a-globin and b-globin mRNA
was much lower. Taken together these data strongly
indicate resveratrol as a strong inducer of HbF and
a selective stimulator of the expression in g-globin genes.
Figure 3. Resveratrol induces increase of g-globin mRNA in human erythroid precursors. Structures of resveratrol and fold increase of a-globin,
b-globin and g-globin mRNA in erythroid precursor cells from human healthy donors (the comparison with the effects of the HbF inducer
mithramycin are shown).
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Hemoglobin
Rapamycin (Fig. 4), a lipophilic macrolide isolated from
a strain of Streptomyces hygroscopicus found in a soil
from Easter Island (known by the inhabitants as Rapa
Nui) (112,113), is of great interest for possible treatment
of b-thalassemia. We recently demonstrated that rapa-
mycin induces erythroid differentiation of K562 cells
and increases HbF production in primary human
erythroid precursor cells (114). Interestingly, Rapamycin
(as Sirolimus or Rapamune) was approved by the U.S.
Food and Drug Administration for prevention of acute
rejection in renal transplant recipients. Moreover, the
dosages we found effective in vitro are very similar to
those described to be present in the blood of kidney
transplanted patients treated with rapamycin (115). In a
more recent paper, we determined whether rapamycin
treatment stimulates production of HbF in cultures
of erythroid precursors isolated from b-thalassemia
patients differing widely with respect to their potential
to produce HbF, ranging from 4.6% to 93.7% of total
Hb. The results indicated that: (i) rapamycin increases
HbF, even if the starting levels of HbF were sharply
different (lower part of Fig. 4), (ii) rapamycin increases
the overall Hb content/cell, (iii) the inducing effects of
rapamycin are selective for g-globin mRNA accumula-
tion, being only minor for b-globin and none for a-globin
mRNAs and (iv) there is a strong correlation between the
increase in the HbF and the increase in g-globin mRNA
content (116).
The interest in rapamycin-inducing HbF increase is
related to the fact that this effect is not associated with
cytotoxicity and cell growth inhibition, in contrast to
effects observed with several other inducers (114). As far
as mechanism of action of this and related compounds is
concerned, it was found that rapamycin-mediated ery-
throid induction is associated with a decrease of
phosphorylation of a-p-S6 ribosomal protein and with a
hyper phosphorylation of 4E-BP-1 (116). Furthermore,
we found that inactivation of both 4E-BP-1 and p70-S6K
are required steps sufficient to induce erythroid differ-
entiation. In fact, we induced differentiation when these
molecular events were simultaneously produced by a
mixture of drugs involved in downstream alterations of
the FRAP-mTOR signal transduction pathway (116).
Figure 4. Induction of HbF by rapamycin. Molecular structure of rapamycin, isolated from a strain of S. hygroscopicus found in the soil of Easter
Island. The effects of rapamycin on HbF production are shown in lower side of the panel. HbF was analyzed by HPLC in erythroid precursor cells
from four b-thalassemia patients (open boxes, control untreated cells; black boxes, rapamycin induced cells). The data are from Fibach et al. (116).
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of clinical importance, since this agent is already in use as
an antirejection agent following kidney transplantation
(115). In these patients, rapamycin reaches steady-state
blood concentrations similar to those we found to induce
HbF, suggesting that this and structurally related
molecules, warrant careful evaluation as potential drugs
for stimulation of g-globin gene expression and increase
of HbF in patients with b-thalassemia and SCA
(114,116).
Among rapamycin analogues, everolimus has been
recently demonstrated to be very active in inducing
erythroid differentiation, increase of g-globin gene
expression and HbF production. Everolimus is of interest
since it exhibits improved pharmacokinetics characteris-
tics, increased oral bioavailability, and rapid achievement
of steady-state levels (117).
Final Remarks and Future Perspectives
Induction of HbF in patients affected by b-thalassemia
and sickle cell anemia (SCA) has been suggested as a very
promising approach for the conversion of those patients
to an independency from blood transfusion (14,24–29,67).
Thalassemia and SCA are the major health problems in
developing countries, when affected patients and healthy
carriers are numerous, mainly due to the absence of
genetic counseling and prenatal diagnosis (2,3,55).
It should be pointed out that pharmacological therapy
of b-thalassemia is expected to be crucial for several
developing countries, unable to efficiently sustain the
high-cost clinical management of b-thalassemia patients
requiring regular transfusion regimen, chelation therapy
and advanced hospital facilities. It is well known that, in
addition to ‘direct costs’, blood transfusions required
accurate monitoring of blood safety, by using costly
technologies, some of which are based on multiple
PCR covering all the possible hematological infectious
diseases (55).
Alternative therapeutic approaches, gene therapy
(118,119) and bone-marrow transplantation (120,121)
are interesting strategies, but are expected to be useful
only for a minority of patients, selected on the basis of
biological/genetic parameters and the economic possibi-
lity to sustain these strategies.
On the other hand, large investments by pharmaceutical
companies finalized to the design, production and testing
of novel drugs for the treatment of b-thalassemia is
discouraged by the fact that this pathology is a rare
disease in developed countries, due to the recurrent
campaigns for prevention, genetic counseling and pre-
natal diagnosis (55). Therefore, the search for molecules
exhibiting the property of inducing g-globin gene expres-
sion is of great interest.
This review was finalized to sustain the concept that
among drugs identified from material from the natural
world (for instance extracts from medicinal plants), some
of them might exhibit the capability to augment HbF.
We firmly believe that this field will be exciting from
the scientific point of view, but also represent a hope for
several patients, whose survival will depend on the
possible use of drugs rendering unnecessary blood
transfusion and chelation therapy.
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